|
KMID : 0869620230400040423
|
|
Journal of Korean Society of Hospital Pharmacists
2023 Volume.40 No. 4 p.423 ~ p.432
|
|
|
SGLT2 Inhibitors Reduce Uric Acid-Related Adverse Events in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
|
|
Shin Young-In
Park Jung-Kyu
Kim Ji-Hae
Ah Young-Mi
Choi Hye-Duck
|
|
|
Abstract
|
|
|
Background : Recent studies demonstrated that sodium glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects including the uric acid lowering effect. However, further research is needed to determine whether the uric acid reduction effect actually leads to improvement in gout or hyperuricemia.
Objective : We conducted a systematic review and meta-analysis to evaluate the effect of SGLT2 inhibitors on reducing uric acid-related adverse events in patients with type 2 diabetes mellitus.
Methods : We assessed the risk of uric acid-related adverse events including gout, hyperuricemia, blood uric acid increase, and urolithiasis with SGLT2 inhibitors treatment compared to controls (placebo or other hypoglycemic agents). In addition, we conducted the risk of all and serious adverse event rates.
Results : Results of this meta-analysis, including 9 studies, showed that the risk of uric acid-related adverse events was significantly reduced in patients on SGLT2 inhibitors treatment than in controls (OR=0.692; 95% CI 0.560?0.856). Also, in patients on SGLT2 inhibitors treatment, the risk of serious adverse events decreased significantly (OR=0.674; 95% CI: 0.491?0.926). The risk of overall adverse events was not significantly different between the treatment and control groups.
Conclusion : The results of this study showed that SGLT2 inhibitors reduce uric acid-related adverse events and serious adverse events. These results provide evidence for the safe and effective use of SGLT2 inhibitors.
|
|
|
KEYWORD
|
|
|
SGLT2 inhibitor, Type 2 diabetes mellitus, Uric acid, Adverse events
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|